Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMUR2 | Q9GZQ4 | 2/20 | 0.44 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.44 |
| ▸ | CXCL8 | P10145 | 8/20 | 0.43 |
| ▸ | CTSL | P07711 | 3/20 | 0.41 |
| ▸ | CTSS | P25774 | 3/20 | 0.41 |
| ▸ | CTSK | P43235 | 3/20 | 0.41 |
| ▸ | CTSH | P09668 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23572611 | 1.00 | NMUR2 (0.44) | NMUR2NMUR1CXCL8CTSLCTSS | |
| SCHEMBL23572613 | 1.00 | NMUR2 (0.44) | NMUR2NMUR1CXCL8CTSLCTSS | |
| SCHEMBL23572612 | 1.00 | NMUR2 (0.44) | NMUR2NMUR1CXCL8CTSLCTSS | |
| SCHEMBL30819303 | 0.89 | NMUR2 (0.39) | NMUR2NMUR1CXCL8OPRM1OPRD1 | |
| SCHEMBL23600922 | 0.89 | NMUR2 (0.39) | NMUR2NMUR1CXCL8OPRM1OPRD1 | |
| SCHEMBL23600921 | 0.89 | NMUR2 (0.39) | NMUR2NMUR1CXCL8OPRM1OPRD1 | |
| SCHEMBL30872268 | 0.84 | CAPN1 (0.46) | CXCL8CTSLCTSSCTSKCTSH | |
| SCHEMBL31157707 | 0.83 | CTSL (0.51) | CXCL8CTSLCTSSCTSKCTSH | |
| SCHEMBL23572621 | 0.82 | CXCL8 (0.48) | CXCL8CTSLCTSSCTSKCTSH | |
| SCHEMBL23572657 | 0.82 | APLNR (0.39) | NMUR2NMUR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210196717-A1 | TOLL-LIKE RECEPTOR 4 (TLR4) INHIBITORS AND USE THEREOF | BAR-ILAN UNIVERSITY (IL) | 2021-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210196717-A1 | TOLL-LIKE RECEPTOR 4 (TLR4) INHIBITORS AND USE THEREOF | TLR4, TLR1, TLR3 | NMUR2 3019/4885NMUR1 2527/4885CXCL8 922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.